fashion -WSS

fashion

author：comprehensive 2025-10-01 04:33:05 - browse：6

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： UnitedHealth increases loan offers after Change Healthcare outage

WSS

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Medicare to cover more brain scans for Alzheimer’s patients

FDA approves RSV monoclonal antibody for infants, toddlers

Leading voice in opioid treatment defends methadone clinic system

In early work, researchers turn to CRISPR to treat Alzheimer's

knowledge

fashion

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Startup Neumora takes a novel depression drug to Phase 3

Anesthesiologist group: stop taking Ozempic before surgery

Doctors find melanoma drugs effective against rare brain cancer

Medical leaders decry Supreme Court decision on affirmative action

Neuroscience’s long legacy of racism

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Moonlake's readout produced a cash windfall. Risks remain

Argenx readies a blockbuster opportunity with drug for autoimmune disease

hotspot

In early work, researchers turn to CRISPR to treat Alzheimer's

Sanders adds drug shortage policies to pandemic preparedness bill

Plastic surgeons increase patient psychiatric screenings

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Google and Epic fight stronger regulation of AI in health care

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

focus

entertainment

explore

focus